Scalp hair loss is an underreported adverse event of somatostatin analogs therapy that in severe cases may require treatment withdrawal. It can be related to an acute decrease in GH / IGF ‐1 levels, but a direct effect cannot be ruled out.
CITATION STYLE
Alvarez‐Escola, C., Cárdenas‐Salas, J. J., Pelegrina, B., Sanz‐Valtierra, A., & Lecumberri, B. (2015). Severe scalp hair loss in a female patient with acromegaly treated with lanreotide autogel after unsuccessful surgery. Clinical Case Reports, 3(11), 945–948. https://doi.org/10.1002/ccr3.388
Mendeley helps you to discover research relevant for your work.